J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

We’re conducting a 3-minute survey that tracks the mood across the industry — science, finance, hiring and regulation

The new for-profit spinoff from the AI research group FutureHouse has raised a $70 million seed round, the latest funding behind the nascent idea of

Insmed said it is discontinuing work on Brinsupri in a form of chronic rhinosinusitis after the inflammation drug failed a Phase 2b study. The Bridgewater,

Early returns suggest that Takeda’s $4 billion immunology bet appears to be paying off. Takeda said Thursday that its drug zasocitinib succeeded in two Phase